Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Targeting Resistant Prostate Cancer With ATR and PARP Inhibition (TRAP Trial)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03787680
Recruitment Status : Active, not recruiting
First Posted : December 26, 2018
Last Update Posted : June 9, 2021
Sponsor:
Information provided by (Responsible Party):
University of Michigan Rogel Cancer Center

Brief Summary:
The purpose of this study is to test the effectiveness (how well the drugs work), safety, and tolerability of the investigational drug combination of olaparib and AZD6738 for all patients with metastatic castration-resistant prostate cancer.

Condition or disease Intervention/treatment Phase
Prostate Cancer Drug: Olaparib Drug: AZD6738 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 49 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multi-Center Phase II Study Testing the Activity of Olaparib and AZD6738 (ATR Inhibitor) in Metastatic Castration-Resistant Prostate Cancer
Actual Study Start Date : October 31, 2019
Estimated Primary Completion Date : November 2021
Estimated Study Completion Date : November 2025

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Prostate Cancer
Drug Information available for: Olaparib

Arm Intervention/treatment
Experimental: Cohort 1 (DRPro)
Patients with metastatic castration-resistant prostate cancer (mCRPC) who are DNA repair proficient (DRPro).
Drug: Olaparib
300 mg by mouth twice a day for days 1-28 of a 28-day cycle.
Other Names:
  • AZD2281
  • ceralasertib

Drug: AZD6738
160 mg by mouth daily for days 1-7 of a 28-day cycle.

Experimental: Cohort 2 (DRDef)
Patients with metastatic castration-resistant prostate cancer (mCRPC) who are DNA repair deficient (DRDef).
Drug: Olaparib
300 mg by mouth twice a day for days 1-28 of a 28-day cycle.
Other Names:
  • AZD2281
  • ceralasertib

Drug: AZD6738
160 mg by mouth daily for days 1-7 of a 28-day cycle.




Primary Outcome Measures :
  1. Rate of response (Complete Response [CR] or Partial Response [PR]) in DNA repair proficient (DRPro) patients [ Time Frame: Up to 30 days after study completion (an average of 1 year) ]
    Evaluated per radiographic response according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or by Prostate Specific Antigen (PSA) (≥50% decline).


Secondary Outcome Measures :
  1. Rate of response (Complete Response [CR] or Partial Response [PR]) in DNA repair deficient (DRDef) patients [ Time Frame: Up to 30 days after study completion (an average of 1 year for study completion) ]
    Evaluated per radiographic response according to RECIST v1.1 or PSA (≥50% decline).

  2. Progression-free survival (PFS) in DRPro patients [ Time Frame: Up to 30 days after study completion (an average of 1 year for study completion) ]
    Duration of time from start of treatment to time of progression (based only on radiographic progression or clinical decline/death).

  3. Progression-free survival (PFS) in DRDef patients [ Time Frame: Up to 30 days after study completion (an average of 1 year for study completion) ]
    Duration of time from start of treatment to time of progression (based only on radiographic progression or clinical decline/death).

  4. Radiographic response rate in DRPro patients [ Time Frame: Up to 30 days after study completion (an average of 1 year for study completion) ]
    Evaluated according to RECIST v1.1.

  5. Radiographic response rate in DRDef patients [ Time Frame: Up to 30 days after study completion (an average of 1 year for study completion) ]
    Evaluated according to RECIST v1.1.

  6. PSA progression-free survival in DRPro patients [ Time Frame: Up to 30 days after study completion (an average of 1 year for study completion) ]
    Composite of survival and duration of PSA control as defined by time from start of therapy to first PSA increase ≥ 25% and ≥2 ng/ml above the nadir and confirmed by a second value at or beyond 4 weeks later.

  7. PSA progression-free survival in DRDef patients [ Time Frame: Up to 30 days after study completion (an average of 1 year for study completion) ]
    Composite of survival and duration of PSA control as defined by time from start of therapy to first PSA increase ≥ 25% and ≥2 ng/ml above the nadir and confirmed by a second value at or beyond 4 weeks later.

  8. PSA response rate in DRPro patients [ Time Frame: Up to 30 days after study completion (an average of 1 year for study completion) ]
    Rate of achieving PSA response rate of ≤ 0.2 ng/ml, 50% decline, or 90% decline from entry PSA and confirmed 4 weeks later

  9. PSA response rate in DRDef patients [ Time Frame: Up to 30 days after study completion (an average of 1 year for study completion) ]
    Rate of achieving PSA response rate of ≤ 0.2 ng/ml, 50% decline, or 90% decline from entry PSA and confirmed 4 weeks later

  10. Duration of combined radiographic and PSA response in DRPro patients [ Time Frame: Up to 30 days after study completion (an average of 1 year for study completion) ]
    Time from first documented response (RECIST v1.1 CR/PR or PSA decline ≥50%) until death, recurrent or progressive disease (based on RECIST v1.1) or first PSA increase ≥ 25% and ≥2 ng/ml above the PSA nadir.

  11. Duration of combined radiographic and PSA response in DRDef patients [ Time Frame: Up to 30 days after study completion (an average of 1 year for study completion) ]
    Time from first documented response (RECIST v1.1 CR/PR or PSA decline ≥50%) until death, recurrent or progressive disease (based on RECIST v1.1) or first PSA increase ≥ 25% and ≥2 ng/ml above the PSA nadir.

  12. Adverse Events [ Time Frame: Up to 30 days after study completion (an average of 1 year for study completion) ]
    NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5.0

  13. Incidence of Myelodysplastic Syndrome (MDS), acute myeloid leukemia (AML) and new primary malignancy [ Time Frame: Up to 5 years after study completion (an average of 1 year for study completion) ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Provision of informed consent prior to any study specific procedures
  2. Male ages 18 years and older at time of signing the informed consent form
  3. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 within 42 days prior to registration
  4. Histologic or cytologic proof of prostate adenocarcinoma (excluding small-cell or neuroendocrine pathologies)
  5. Metastatic prostate cancer on CT, MRI or Bone scan
  6. Must have disease progression (while testosterone level is under 50 ng/dl) on prior therapy prior to study entry defined as one (or more) of the following:

    1. PSA progression defined as continuously rising PSA values measured a minimum of 1 week apart with a minimal starting value of 1.0 ng/mL
    2. Progression of bidimensionally measurable soft tissue or nodal metastasis by CT or MRI based on RECIST, v1.1
  7. Prior treatment with at least one of the following:

    1. One line of therapy in mCRPC
    2. Second generation anti-androgen (e.g. abiraterone, enzalutamide or apalutamide) within the hormone-sensitive phase of disease AND progression occurs while on therapy
  8. Patients must be withdrawn from prior therapy for ≥3 weeks (patients may remain on prior prednisone up to 10 mg total daily exposure at provider's discretion) at planned time of treatment start.
  9. Agree to undergo a biopsy of at least one metastatic site (if feasible) to determine DNA repair status, unless prior metastatic tissue underwent next-generation sequencing in a CLIA certified lab or known germline loss of BRCA1, BRCA2 or ATM. If no site is reachable, or first biopsy insufficient/unsuccessful, circulating tumor DNA may be obtained.
  10. Treated with continuous androgen deprivation therapy (either surgical castration or LHRH agonist/antagonist) with documented castrate level of serum testosterone (<50 ng/dL). A stable dose of bisphosphonate or denosumab for bone metastases should be continued as long as started at least 5 days prior to C1D1 planned start day.
  11. At the time of planned treatment start (C1D1), at least 21 or more days will have elapsed from palliative radiation (with the exception of radiation to >30% of bone marrow or with a wide field of radiation, this requires 28 or more days).
  12. Patient must have normal organ and bone marrow function measured within 42 days prior to registration as defined below

    1. Hemoglobin ≥10 g/dL (with no blood transfusion or erythropoietin use within the past 42 days)
    2. Absolute neutrophil count ≥1.5x109/L
    3. Platelet count ≥100x109/L (with no platelet transfusions within last 42 days)
    4. Total bilirubin <1.5x ULN (unless the patient has documented Gilbert's disease and <2.0x ULN should be used)
    5. AST or ALT ≤ 2.5x ULN, unless liver metastases are present in which case they cannot be ≥5x ULN
    6. Glomerular filtration rate (GFR) ≥51 mL/min, as assessed using the Cockcroft- Gault equation
  13. Estimated life expectancy ≥16 weeks
  14. Male patients who are sexually active must be willing to use barrier contraception for the duration of the study and for 1 week after the last study drug administration, with all sexual partners. Male patients must use a condom during treatment and for 6 months after the last dose of study drug(s) when having sexual intercourse with a pregnant woman or with a woman of childbearing potential and must not donate sperm for 6 months after the last dose of study drug. Female partners of male patients should also use a highly effective form of contraception (per protocol) for 6 months after the last dose of study drug(s) if they are of childbearing potential. True abstinence is an acceptable form of contraception and must be documented as such.
  15. Patient is willing and able to comply with the protocol for the duration of the study, including undergoing biopsy (if warranted), treatment, scheduled visits and examinations

Exclusion Criteria:

  1. A diagnosis of ataxia telangiectasia
  2. Prior treatment with a PARP inhibitor (e.g. olaparib, veliparib, niraparib, rucaparib), AZD6738 or other DNA-damage response agents (e.g. cisplatin or carboplatin)
  3. Cytotoxic chemotherapy, first- or second-generation antiandrogen or CYP17 inhibitors are not permitted within 21 days or 5 half-lives of registration (whichever is longest) of planned treatment start. For clarity, enzalutamide requires 5 weeks washout.
  4. Major surgery < 2 weeks prior to enrolment; patients must have recovered from any effects of major surgery
  5. Persistent toxicities (≥CTCAE Grade 2) caused by previous cancer therapy, besides Grade 2 alopecia and Grade 2 neuropathy (these are allowed).
  6. Patients with current or prior MDS/AML or with features suggestive of MDS/AML
  7. Any other malignancy which has been active or treated within the past 3 years, with the exception of non-melanomatous skin cancer, or Ta bladder cancer
  8. Patients with active brain metastases are excluded because of unknown penetration into the CNS. A confirmatory scan for asymptomatic patients is not required. Patients with a history of treated central nervous system (CNS) metastases are eligible provided they meet all of the following criteria: disease outside the CNS is present, no clinical evidence of progression since completion of CNS-directed therapy, minimum 3 weeks between completion of radiotherapy and registration and recovery from significant (Grade ≥ 3) acute toxicity with no ongoing requirement for >10 mg of prednisone per day or an equivalent dose of other corticosteroid. If a patient must remain on steroids, they must have started the steady dose at least 28 days prior to treatment. Patients with spinal cord compression unless considered to have received definitive treatment for this and evidence of clinically stable disease for 28 days prior to study treatment.
  9. Any of the following cardiac disease currently or within the last 6 months:

    1. Unstable angina pectoris
    2. Congestive heart failure (by New York Heart Association ≥ Class 2) or known reduced LVEF < 55%
    3. Acute myocardial infarction
    4. Conduction abnormality not controlled with pacemaker or medication (e.g. complete left bundle branch block or third-degree heart block)
    5. Significant ventricular or supraventricular arrhythmias (patients with chronic rate-controlled atrial fibrillation in the absence of other cardiac abnormalities are eligible).
    6. Uncontrolled hypertension (Grade 2 or above) requiring urgent (for example, adjusting medications within 24 hours) clinical intervention
    7. Patients at risk of brain perfusion problems, e.g. TIAs or history of pre- syncope or syncopal episodes unexplained by reversible causes
  10. Mean resting corrected QT interval >450, obtained from 3 ECGs 2-5 minutes apart using the Fredericia formula. Absence of any factors that increase the risk of QTc prolongation or risk of arrhythmic such as congenital long QT syndrome, immediate family history of long QT syndrome or unexplained sudden death under 40 year of age. Patients with relative hypotension (<90/60 mmHg) or previously known clinically relevant orthostatic hypotension defined as a postural hypotension ≥20 mmHg
  11. Concomitant use of known potent or moderate cytochrome P (CYP) 3A inhibitors (e.g. itraconazole, ciprofloxacin, diltiazem) require 2-week washout prior to planned C1D1. Concomitant use of strong or moderate CYP3A inducers (e.g. phenobarbital, enzalutamide, modafinil require 5-week washout for enzalutamide or phenobarbital and 3 week washout for all others, per protocol.
  12. As judged by the Investigator, any evidence of severe or uncontrolled systemic diseases that places the patient at unacceptable risk of toxicity or non-compliance. Examples include, but are not limited to, active bleeding diatheses, renal transplant, uncontrolled major seizure disorder, severe COPD, superior vena cava syndrome, extensive bilateral lung disease on High Resolution CT scan, severe Parkinson's disease, active inflammatory bowel disease, psychiatric condition, immunocompromised patients or active infection including any patient known to have hepatitis B, hepatitis C and human immunodeficiency virus (HIV) or requiring systemic antibiotics, antifungals or antiviral drugs. Screening for chronic conditions is not required
  13. A known hypersensitivity to olaparib, AZD6738 or any excipient of the product or any contraindication to the combination anti-cancer agent as per local prescribing information
  14. Patients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with the absorption of the study medication, refractory nausea and vomiting, chronic gastrointestinal diseases or previous significant bowel resection, with clinically significant sequelae that would preclude adequate absorption of AZD6738
  15. Previous allogenic bone marrow transplant or double umbilical cord blood transplantation (dUCBT).
  16. Whole blood transfusions in the last 120 days prior to entry to the study (packed red blood cells and platelet transfusions are acceptable, for timing refer to inclusion criteria no.12)
  17. Involvement in the planning and/or conduct of the study
  18. Judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions and requirements.
  19. Previous enrolment in the present study.
  20. Has received a live vaccination with 2 weeks of enrollment.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03787680


Locations
Layout table for location information
United States, Michigan
University of Michigan Hospital
Ann Arbor, Michigan, United States, 48109
Wayne State University/Karmanos Cancer Institute
Detroit, Michigan, United States, 48201
United States, Virginia
University of Virginia Health System
Charlottesville, Virginia, United States, 22908
Sponsors and Collaborators
University of Michigan Rogel Cancer Center
Investigators
Layout table for investigator information
Principal Investigator: Zachery Reichert, M.D. University of Michigan Rogel Cancer Center
Layout table for additonal information
Responsible Party: University of Michigan Rogel Cancer Center
ClinicalTrials.gov Identifier: NCT03787680    
Other Study ID Numbers: UMCC 2018.108
HUM00152799 ( Other Identifier: University of Michigan )
First Posted: December 26, 2018    Key Record Dates
Last Update Posted: June 9, 2021
Last Verified: June 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Prostatic Diseases
Olaparib
Poly(ADP-ribose) Polymerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents